Aptose Biosciences Warns of Insufficient Cash to Fund Operations
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.1× avg).
Summary
Aptose Biosciences has disclosed it does not possess sufficient cash to fund its ongoing operations. This critical announcement directly contradicts the previous positive resolution for the financially distressed company, where shareholders approved an acquisition by Hanmi Pharmaceutical for C$2.41 per share on March 31, 2026. The current cash shortage indicates that the acquisition may be delayed, insufficient, or has not yet closed, posing an immediate and severe threat to the company's viability. This news significantly elevates the risk of bankruptcy, delisting, or highly dilutive emergency financing. Traders should monitor for updates on the acquisition status or any new capital raise initiatives.
At the time of this announcement, APTOF was trading at $1.70 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.64 to $4.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.